At the news
? NEUTRALIMPACT 3/10 8-K filed May 5, 2026 at 16:12 ET
Cytokinetics released a corporate presentation updating on commercial launch progress of MYQORZO (aficamten) for oHCM, positive ACACIA-HCM trial results for nHCM, and pipeline advancement. The filing is routine with no new material events or financial disclosures beyond previously announced data and launch metrics.
- Cash, cash equivalents and investments of approximately $1.1B as of 3/31/26
- MYQORZO launched in U.S. and China in January 2026; EU approval secured
- 680 patients prescribed MYQORZO as of 3/31/26, growing to 1,100 as of 4/30/26
- 1,400+ REMS-certified HCPs as of 3/31/26; average 2.4 prescriptions per HCP
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access